Press Release

« Back
Protagonist Therapeutics to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

NEWARK, Calif., Dec. 4, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., the company's President and Chief Executive Officer, will participate in an analyst-led fireside chat, to be held at 8 am ET on December 14 at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference. The BMO Capital Markets conference is taking place at the Westin Grand Central Hotel in New York, NY.

Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)

A live and archived audio webcast of the presentation can be accessed by visiting the Investors page of Protagonist Therapeutics corporate website at http://investors.protagonist-inc.com.

About Protagonist Therapeutics
Protagonist Therapeutics is a clinical development-stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to address significant unmet medical needs. Its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. Lead oral peptide candidates, PTG-100 and PTG-200, are based on this approach. The alfa-4-beta-7 integrin antagonist PTG-100 is currently in Phase 2b clinical trials for moderate-to-severe ulcerative colitis, and the company's interleukin-23 receptor antagonist PTG-200 is currently being studied in a Phase 1 clinical trial in healthy volunteers in support of its development as a potential treatment for Crohn's disease.  The company recently entered into a worldwide license and collaboration agreement with Janssen Biotech for the clinical development of PTG-200.  Protagonist has also applied its platform to other disease areas and is developing an injectable hepcidin mimetic, PTG-300, for the treatment of rare diseases such as beta-thalassemia and myelodysplastic syndromes (MDS). PTG-300 is currently being studied in a Phase 1 clinical trial.

Protagonist is headquartered in Newark, California with pre-clinical and clinical staff in California, and discovery operations both in California and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.

 

View original content with multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-at-the-bmo-capital-markets-2017-prescriptions-for-success-healthcare-conference-300565700.html

SOURCE Protagonist Therapeutics, Inc.

Joan Kureczka, Kureczka/Martin Associates; Tel: +1-415-821-2413; Joan@Kureczka-martin.com OR For Investors: The Trout Group; Marcy Nanus; +1-646-378-2927; mnanus@troutgroup.com